AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

A cancer diagnosis is an unsettling and unnerving time. From researching treatments to finding out how to adjust your life to fit your diagnosis, it can be stressful to figure out how to best take ...